news
US could purchase over 1.5 million doses of Regeneron’s COVID-19 antibody cocktail
The additional doses of casirivimab and imdevimab, two monoclonal antibodies, will be used in non-hospitalised COVID-19 patients.
List view / Grid view
Regeneron
news
Phase III trial to study REGN-COV2, potential COVID-19 antibody treatment
REGN-COV2 will be evaluated alongside standard-of-care in a Phase III study as part of the COVID-19 RECOVERY trial.
news
Further clinical trials testing Kevzara as COVID-19 therapy to be halted
After Kevzara (sarilumab) did not meet its primary or secondary endpoints in a Phase III trial, Sanofi and Regeneron have said they do not expect to conduct further studies on the drug against COVID-19.
article
Potential COVID-19 therapeutics currently in development
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.
news
Clinical programme to evaluate Kevzara® as COVID-19 treatment begins
Led by Sanofi and Regeneron, clinical trials to examine Kevzara (sarilumab) as an effective COVID-19 treatment will begin in the US.
news
Genome sequencing of first 50,000 UK Biobank participants
UK Biobank has announced a major initiative to sequence the full genomes of 50,000 UK Biobank volunteer participants...
